Back to search results

Understanding Thinking Changes in Breast Cancer Survivors

This study, called TRAC, is looking at how thinking abilities (cognitive function) change over time in women who have survived breast cancer. Researchers will compare breast cancer survivors to healthy women of the same age who have not had cancer. Both groups will complete assessments, including questionnaires about their health and remote cognitive (thinking) tests. For breast cancer survivors, researchers will also review information about their tumor and treatments. The main goal is to understand the effects on thinking within 45 days of joining the study. You may be able to join if you are a woman between 60 and 80 years old, have access to a computer and internet, and meet other health criteria. The study aims to enroll 420 participants.

Study design
This is an observational study, meaning researchers will gather information without providing any interventions. It plans to enroll 420 participants, including breast cancer survivors and healthy volunteers.
What's involved
You would complete sociodemographic questionnaires, deficit accumulation questionnaires, and remote cognitive assessments. If you are a survivor, your tumor and treatment variables will also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for examining cognitive effects is measured within 45 days of your consent to participate.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06334354

A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)

Recruiting
Not specifiedAges 60–80Observational
Memorial Sloan Kettering Cancer Center
~420 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:AssessmentsAssessment (Survivors Only)APOE and DNA Isolation

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
examine cognitive effects
Measured over within 45 days of participant consent

Conditions

Breast Cancer Survivors

Explore related trials

Breast CarcinomaCognitive aging

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • James Root, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

James Root, PhD
[email protected]
646-888-0035
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Per medical record and/or self-report, identifies as female
Per medical record and/or self-report, currently age 60-80
Per self-report, has access to a computer and internet connectivity
Score of \<11 on Blessed Orientation-Memory-Concentration Test (BOMC)
As per medical record or self-report, if currently taking psychoactive medications (including but not limited to antidepressants and anxiolytics), dose must have been stable at least two months prior to enrollment.
English fluent (as per self-report, fluency of "well" or "very well", and having a reasonable comprehension of the study conversation in the opinion of the research staff)\*\*
Per medical record and/or self-report, history of stage 0-3 breast cancer diagnosed between 50-60 years of age
Per medical record and/or self-report, no evidence of disease (NED)
Per self-report, no history of breast cancer
Language verification: For both survivors and controls, prior to enrollment, all will be asked the following two questions by a CRC to verify English fluency necessary for participation in the study:

Exclusion

As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.)
As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life, or required cognitive rehabilitation
As per medical record or self-report, a diagnosis of a major Axis I psychiatric disorder including Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder.
As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids)
As per medical record or self-report, use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for lupus.
As per medical record or self-report, participation in a conflicting (overlapping neurocognitive assessments) research study (i.e. MSK 18-294)
As per medical record or self-report, history of cancer recurrence
As per medical record or self-report, any history of another cancer except nonmelanoma skin cancer or first breast cancer (a secondary breast cancer is exclusionary)
As per medical record or self-report, breast cancer only treated with surgery
As per medical record or self-report, history of treatment using radiation, chemotherapy, and/or Tamoxifen or Aromatase-inhibitors
As per medical record or self-report, any history of cancer except non-melanoma skin cancer

What this trial measures

  • examine cognitive effectswithin 45 days of participant consent

    of remote cancer diagnosis and treatment and potential association with increased/accelerated deficit accumulation in older survivors.The primary outcome is cognitive performance, as measured by CogSuite aggregate intra-individual variability, the average intra-individual variability across the subtests. Cognition will be assessed using the CogSuite battery of five subtests: 1) Attention Network Test; 2) Mental Rotation; 3) Stop Signal Delay; 4) N-back; and 5) Psychomotor Speed measures.